Related Experiment Video
Updated: Jun 7, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
The acute hepatic porphyrias: current status and future challenges
Marko Siegesmund1, Anne-Moniek van Tuyll van Serooskerken, Pamela Poblete-Gutiérrez
1Department of Dermatology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Best Practice & Research. Clinical Gastroenterology
|October 20, 2010
Summary
The porphyrias are inherited metabolic disorders affecting haem biosynthesis. Acute forms can cause life-threatening attacks, necessitating precise diagnosis and improved management strategies.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Porphyrias are inherited metabolic disorders stemming from enzyme deficiencies in haem biosynthesis.
- Clinical classification distinguishes between acute and non-acute forms, with acute attacks posing significant mortality risks.
- Acute hepatic porphyrias include acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and ALA dehydratase deficiency porphyria.
Purpose of the Study:
- To provide an overview of the current understanding of acute hepatic porphyrias.
- To discuss the pathogenesis, clinical presentation, diagnostics, and therapy of these conditions.
- To highlight existing and future challenges in managing acute hepatic porphyrias.
Main Methods:
- Review of existing literature on porphyria pathogenesis.
- Analysis of clinical manifestations and diagnostic criteria for acute hepatic porphyrias.
- Evaluation of current therapeutic approaches and future directions.
Main Results:
- Acute hepatic porphyrias result from specific enzyme deficiencies in the haem biosynthesis pathway.
- Diagnosis can be challenging due to overlapping clinical and biochemical features.
- Current therapeutic options are limited and primarily symptomatic.
Conclusions:
- Accurate diagnosis and effective management of acute hepatic porphyrias remain critical due to potential life-threatening attacks.
- Further research is needed to develop more targeted and effective therapies.
- Addressing diagnostic and therapeutic challenges is essential for improving patient outcomes.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...